Arrowhead Ducks Investor Suit Over Hep B Drug Trial
After tentatively greenlighting investors' claims earlier this year that Arrowhead Research Corp. overstated hepatitis B vaccine trial results, a California federal judge tossed the proposed class action on Tuesday, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article